Schedule 13D ownership disclosure
Enliven Therapeutics Inc
Security class unavailable · CUSIP: 29337E102
Event date: 2023-02-23
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- Unavailable
- Percent of class
- 21.8000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000947871-23-000250
- Form type
- SC 13D
- Filer
- Enliven Therapeutics, Inc.
- CIK
- CIK 1672619
- Filed
- Feb 28, 2023
- Reporting period
- Feb 23, 2023
- Description
- Schedule 13D beneficial ownership